{
    "@graph": [
        {
            "@id": "gnd:14373945X",
            "sameAs": "Donev, Rossen"
        },
        {
            "@id": "gnd:4745193-2",
            "sameAs": "Protein-Protein-Wechselwirkung"
        },
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A1016513690",
            "@type": "bibo:Book",
            "P1053": "xi, 282 Seiten",
            "description": "Illustrationen",
            "identifier": [
                "(ppn)1016513690",
                "(firstid)GBV:1016513690",
                "(isbn13)9780128143421"
            ],
            "publisher": "Academic Press",
            "subject": [
                "(classificationName=bk, id=181571129)35.76 - Aminosäuren, Peptide, Eiweiße",
                "(classificationName=linseach:mapping)che",
                "(classificationName=linseach:mapping)bio",
                "(classificationName=linseach:mapping)meda",
                "(classificationName=bk, id=18157179X)44.42 - Pharmazeutische Chemie"
            ],
            "title": "Protein-Protein interactions in human disease / edited by Rossen Donev ; Part B",
            "abstract": [
                "3.1. Protein-Protein Interaction -- 3.2. Conservation and Pathogenicity Analysis -- 3.3. Stability Analysis -- 3.4. Molecular Docking Analysis -- 3.5. Molecular Dynamics Simulations (MDS) -- 4. Discussion -- 5. Conclusion -- Acknowledgments -- References -- Chapter Nine: Human Interactomics: Comparative Analysis of Different Protein Interaction Resources and Construction of a ... -- 1. Introduction -- 2. Primary Databases of PPIs -- 3. Meta-databases Integrating and Unifying Multiple PPI Resources -- 4. Human Interactome: Proteome-Wide Human PPI Compendiums -- 5. Human Drug-Target Interaction Resources -- 6. Cancer Genes/Proteins Compendium -- 7. Construction of a PPI Network With Cancer Genes -- 8. Cancer Protein-Drug Bipartite Network Reveals Druggable Modules -- References -- Back Cover",
                "Front Cover -- Protein-Protein Interactions in Human Disease, Part B -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design -- 1. Introduction -- 2. Methods to Study PPIs and Their Inhibition -- 2.1. Coimmunoprecipitation -- 2.2. Pull-Down Assay -- 2.3. Proximity Ligation Assay -- 2.4. Enzyme Fragment Complementation Assay (PathHunter Assay) -- 2.5. Surface Plasmon Resonance -- 2.6. Mutational Studies to Identify Hot Spots in PPI -- 3. Inhibition of Dimerization of Protein and PPI -- 4. Design of Compounds Based on Protein Interface -- 4.1. Structure-Based Drug Design -- 4.2. Fragment-Based Discovery in PPI Inhibition -- 4.3. High-Throughput Screening -- 5. Homodimers -- 5.1. G-Protein-Coupled Receptors -- 5.2. Receptor Tyrosine Kinase-Like Orphan Receptor 2 -- 5.3. Glucocorticoid Receptor -- 5.4. Amyloid Precursor Protein Dimers -- 5.5. EGFR Homodimers -- 6. Heterodimerization of Proteins and Inhibition -- 6.1. p45-p75 Heterodimers -- 6.2. IL-6-IL-6RÎ± -- 6.3. Epidermal Growth Factor Receptors -- 6.3.1. Structure of ECDs of Proteins -- 6.3.2. Design Concept -- 6.4. PD-1-PD-L1 Pathway -- 6.5. CD-28/CD-80 -- 6.6. CD2-CD58 Interactions and the Design of Multicyclic Peptides -- 6.6.1. Multicyclic Peptide Approach -- References -- Chapter Two: Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years Old -- 1. Introduction -- 2. PPIs in Transmembrane Signaling -- 2.1. Intramembrane and Cytoplasmic Interactions -- 2.1.1. Single-Chain Receptors -- 2.1.2. Multichain Receptors -- 2.2. Transmembrane Signaling and Viral Evasion Strategies: Evolutionary and Molecular Aspects -- 3. Intramembrane PPIs as a Therapeutic Target -- 3.1. Cancer -- 3.1.1. Nonsmall Cell Lung Cancer -- 3.1.2. Pancreatic Cancer",
                "3.2. Autoimmune Diseases -- 3.2.1. Targeting T Cell Receptor -- 3.2.2. Targeting TREM-1 -- 3.3. Sepsis -- 3.4. Thrombosis -- 3.5. Retinopathy -- 4. Conclusions -- Acknowledgments -- References -- Further Reading -- Chapter Three: Targeting the Architecture of Deregulated Protein Complexes in Cancer -- 1. Introduction -- 2. RAS:RAF Signalosome and Network -- 2.1. Background -- 2.2. Small G Proteins of the RAS Family and RAF Family Serine-Threonine Kinases -- 2.3. Physiological and Pathophysiological Functions -- 2.4. Pharmacological Targeting of RAS:RAF Complexes -- 3. PKA Signalosome and Network -- 3.1. Background -- 3.2. Macromolecular PKA Complexes -- 3.3. Pathological PKA Functions -- 3.4. Pharmacological Targeting of PKA Emanating PPIs -- 4. MYC:MAX Signalosome and Network -- 4.1. The MYC:MAX Network -- 4.2. Physiological and Oncogenic Functions -- 4.3. Pharmacological Interference -- 5. Conclusions -- Acknowledgments -- References -- Chapter Four: Multifaceted Nucleolin Protein and Its Molecular Partners in Oncogenesis -- 1. Introduction -- 2. Structure of Nucleolin -- 3. Role of Nucleolin in Ribosome Biogenesis and Gene Expression in Cancer Cells -- 4. Functions of Nucleolin in DNA Repair and Genome Stability -- 5. Functions of Nucleolin in Cell Division -- 6. Functions of Nucleolin in Cell Survival -- 7. Nucleolin Function in Chemokine Receptor Signaling -- 8. Function of Nucleolin in EGF-TGF-Î² Signaling Pathways -- 9. Nucleolin on Angiogenesis and Lymphangiogenesis -- 10. Nucleolin Function in Epithelial-Mesenchymal Transition -- 11. Nucleolin Functions in Stemness -- 12. Concluding Remarks -- Acknowledgments -- References -- Chapter Five: Subcellular Targeting of Nitric Oxide Synthases Mediated by Their N-Terminal Motifs -- 1. Nitric Oxide and Nitric Oxide Synthases -- 2. Subcellular Targeting of iNOS Mediated by N-Terminal Palmitoylation",
                "3. N-Terminal eNOS Myristoylation and Palmitoylation Mediate Its Subcellular Localization -- 4. nNOS and Its Multiple N-Terminal Localization Signals -- 5. The PDZ Domain of nNOS and Its Interacting Proteins -- 6. Understanding the Promiscuity of Binding Shown by the PDZ Domain of nNOS -- 7. nNOS as a Target in Excitotoxicity -- 8. nNOS as a Target in Duchenne Muscular Dystrophy -- 9. Final Remarks -- References -- Chapter Six: Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases -- 1. Antibacterial Agents -- 1.1. ZipA-FtsZ -- 1.2. Pilicides -- 1.3. DnaN-DnaE1 -- 2. Antiviral PPI Inhibitors -- 2.1. Human Papillomavirus Ori-E1-E2 Interaction -- 2.2. Human Immunodeficiency Virus -- 2.3. HIV Entry Inhibitors -- 2.4. HIV Integrase Inhibitors -- 3. Targeting Host-Host PPIs to Improve Infection Survival -- 3.1. Neutrophil Exocytosis Inhibitors (Nexinhibs) -- 4. Considerations for Targeting PPIs -- References -- Chapter Seven: Defining Pharmacological Targets by Analysis of Virus-Host Protein Interactions -- 1. Cellular Proteins Exist in Complexes -- 2. Discovering Virus-Host Protein Complexes -- 3. Different Pathogens Exploit Similar Cellular Processes -- 4. Viral Proteins Interact With Host Proteins in Complexes -- 5. Development of Small Molecules Disrupting PPIs -- 6. Targeting Virus-Host PPIs With Small Molecules -- 7. Small Molecules Disrupting Host Complexes Implicated in Viral Replication -- 8. Concluding Remarks -- Acknowledgments -- References -- Chapter Eight: Investigating the Influence of Hotspot Mutations in Protein-Protein Interaction of IDH1 Homodimer Protein: ... -- 1. Introduction -- 2. Materials and Methods -- 2.1. Dataset and Protein Modeling -- 2.2. Conservation and Pathogenicity Analysis -- 2.3. Stability Analysis -- 2.4. Molecular Docking and Molecular Dynamics Simulations -- 3. Results"
            ],
            "contributor": "gnd:14373945X",
            "dcterms:contributor": "Technische Informationsbibliothek (TIB)",
            "issued": "2018",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "commercial licence",
            "medium": "rda:termList/RDACarrierType/1044",
            "dcterms:subject": {
                "@id": "gnd:4745193-2"
            },
            "tableOfContents": "http://www.gbv.de/dms/tib-ub-hannover/1016513690.pdf",
            "volume": "111",
            "P30128": "Advances in protein chemistry and structural biology",
            "P60163": "Cambridge, MA"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "sameAs": "http://www.w3.org/2002/07/owl#sameAs",
        "volume": "http://purl.org/ontology/bibo/volume",
        "license": "http://purl.org/dc/terms/license",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "issued": "http://purl.org/dc/terms/issued",
        "title": "http://purl.org/dc/elements/1.1/title",
        "abstract": "http://purl.org/dc/terms/abstract",
        "contributor": {
            "@id": "http://purl.org/dc/terms/contributor",
            "@type": "@id"
        },
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "tableOfContents": "http://purl.org/dc/terms/tableOfContents",
        "description": "http://purl.org/dc/elements/1.1/description",
        "P30128": "http://www.rdaregistry.info/Elements/m/#P30128",
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}